<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578420</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2015-246</org_study_id>
    <nct_id>NCT02578420</nct_id>
  </id_info>
  <brief_title>Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo</brief_title>
  <official_title>Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, very little is known about the mechanisms of open-label placebo treatment and there&#xD;
      is a lack in highly controlled experimental designs. Therefore, the planned project will test&#xD;
      well-established explanatory models of (deceptive) placebo, i.e., (1) expectancy, (2) meaning&#xD;
      response, in an open-label placebo design, investigating their influence on placebo&#xD;
      analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current project will consist of one experimental study and one qualitative study:&#xD;
&#xD;
        1. the effects of open-label, and deceptive placebo administration on placebo analgesia&#xD;
           will be directly compared when both groups have a comparable expectancy-inducing&#xD;
           scientific rationale;&#xD;
&#xD;
        2. subjective meaning models will be assessed by comparing subjective narratives of the&#xD;
           placebo effect in open-label and deceptive placebo groups in a nested qualitative study.&#xD;
&#xD;
      The experimental study will be a randomized experiment with healthy subjects (N=120), and&#xD;
      pain will be induced using a standardized heat pain paradigm (Medoc, Ramatishai, Israel;&#xD;
      thermo-sensory analyzer (TSA)-II). Effects of the experimental conditions will be assessed&#xD;
      both objectively (i.e. heat pain threshold and tolerance) and subjectively (i.e. subjective&#xD;
      pain ratings, pain intensity and unpleasantness). Furthermore, investigators will randomly&#xD;
      select 30 participants to take part in a nested qualitative study in order to qualitatively&#xD;
      assess the meaning response by comparing subjective narratives of the placebo effect in the&#xD;
      open-label and deceptive placebo groups, as well as in the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>subjective intensity and unpleasantness ratings of heat pain tolerance</measure>
    <time_frame>2 hours</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective heat pain tolerance</measure>
    <time_frame>2 hours</time_frame>
    <description>Temperatures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expectancy of Relief Scale (ERS; Erwartungsfragebogen)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Credibility and Effectiveness of the placebo analgesia expectation; adapted Version of the Context Model Questionnaire; Kontextmodellfragebogen (KMF)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>multidimensional sensitivities questionnaire (Mehrdimensionaler Befindlichkeitsfragebogen (MDBF))</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sociodemographic questionnaire (Soziodemographischer Fragebogen (SDD))</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Life Orientation Test (LOT-R)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEO five-factor inventory (NEO-FFI)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire on competence and locus of control (Fragebogen zu Kompetenz- und Kontroll√ºberzeugungen (FKK))</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression Scale (HADS-D)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beliefs in holistic health and holistic treatments; Complementary and Alternative Medicine Beliefs Intentory (CAMBI)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire for Relief Scale (DRS)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective intensity and unpleasantness ratings of heat pain threshold</measure>
    <time_frame>2 hours</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective heat pain threshold</measure>
    <time_frame>2 hours</time_frame>
    <description>Temperatures</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Placebo Effect</condition>
  <condition>Pain</condition>
  <condition>Expectancy</condition>
  <arm_group>
    <arm_group_label>open-label placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants (N=40) will have the information that they are receiving an inert cream (i.e. &quot;placebo&quot;). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that &quot;placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes.&quot; The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deceptive placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants (N=40) will have the information that they are receiving an analgesic cream (&quot;Antidolor, containing &quot;Lidocain&quot;), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants (N=40) will have the information that they are receiving an inert control cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants (N=40) will be told that they are in the &quot;no treatment group&quot; and that they will not receive an analgesic cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>open-label placebo</intervention_name>
    <description>Placebo Cream, openly described as &quot;Placebo&quot;</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>open-label placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>deceptive placebo</intervention_name>
    <description>Placebo Cream, described as &quot;Voltaren, containing Diclofenac&quot;</description>
    <arm_group_label>deceptive placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female adults aged 18-65&#xD;
&#xD;
          -  Healthy by self-report statement, thus no known current or chronic somatic diseases or&#xD;
             psychiatric disorders&#xD;
&#xD;
          -  Right-handedness (Oldfield, 1971),&#xD;
&#xD;
          -  Willing to participate in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medicine or Psychology Students&#xD;
&#xD;
          -  Any acute or chronic disease (chronic pain, hypertension, heart disease, renal&#xD;
             disease, liver disease, diabetes) as well as skin pathologies, neuropathies or nerve&#xD;
             entrapment symptoms, sensory abnormalities affecting the tactile or thermal modality&#xD;
&#xD;
          -  Current medications (psychoactive medication, narcotics, intake of analgesics) or&#xD;
             being currently in psychological or psychiatric treatment&#xD;
&#xD;
          -  Insufficient German language skills to understand the instructions&#xD;
&#xD;
          -  Previous participation in studies using pain assessment (threshold and tolerance) with&#xD;
             Peltier Devices&#xD;
&#xD;
          -  Daily consumption of more than three alcoholic standard beverages per day (a standard&#xD;
             alcoholic beverage is defined as either 3dl beer or 1 dl wine or 2cl spirits)&#xD;
&#xD;
          -  Current or regular drug consumption (THC, cocaine, heroin, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Gaab, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Psychology and Psychotherapy, Department of Psychology, University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

